SAHPRA has strict rules and guidelines on the importing and exporting of medicines. This is stipulated in the Medicines and Related Substances Act (Act 101 of 1965 as amended).

SAPHRA Clarifies Importation Processes

Mokgadi Daphney Fafudi, SAHPRA's Regulatory Compliance Manager,  talks about psychedelic treatment, the registration process, including the Section 21 process.

Cape Talk -  Regulatory Compliance Manager Talks About Psychedelic Treatment

SAHPRA CEO Dr Boitumelo Semete-Makokotlela speaks about the extension of expiry dates of COVID-19 vaccines.

SAFM interview - SAHPRA CEO speaks on vaccine shelf-life extension

SAHPRA has been recently ranked by the WHO at a functional level of maturity (Level 3) according to WHO's global classification system for medical products regulatory authorities.

Podcast - SAHPRA receives accolade from WHO

SA FM Interview - Medicine And Vaccine Safety

The South African Health Products Regulatory Authority (SAHPRA) has registered Cabotegravir (Apretude 600 mg/3ml injection), a long-acting HIV pre-exposure prophylactic.

SAHPRA Registers New Long - Acting HIV Pre - Exposure Prophylaxis

SAFM - Interview With Mafora Matlala On Medicine And Vaccine Safety

Ms Lorraine Danks Chatting About The Backlog Clearance Project On Lesedi FM

Ms Mahlodi Moropa Interview On SAFM About The HIV Prophylactic Injectable

SAFM interview | Mahlodi Moropa speaks about the CAB-LA jab

702 Clement Manyathela Show - Listeners choice feature: Topic: Looking at medical cannabis in South Africa. What is legal and what not? Mokgadi Fafudi, Manager: Regulatory Compliance speaks about cannabis matters from licencing to medicinal cannabis.

Radio 702 Interview - Understanding Cannabis Matters with Mokgadi Fafudi - Part 1

The South African Health Products Regulatory Authority (SAHPRA) has registered Paxlovid, an anti-viral medicine manufactured by Pfizer, to treat COVID-19.

SAHPRA registers Paxlovid

SAHPRA has recalled two batches of Benylin Paediatric Syrup after receiving a report from the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC) regarding the detection of high levels of diethylene glycol.

SAHPRA recalls two batches of Benylin Paediatric Syrup

The South African Health Products Regulatory Authority (SAHPRA) is concerned about the proliferation of falsified, compounded and substandard Glucagon-like Peptide (GLP-1)-containing products being made available to the public via websites, social media platforms and other informal channels. These pose a health risk to the public. SAHPRA cautions the public to not purchase and/or consume such products as their safety, efficacy and quality have not been assessed.

SAHPRA’s position on GLP1 and GIP-GLP1 products that are compounded, substandard and falsified

SAHPRA's Communications & PR Manager shares part of our media statement regarding  the recommendartion that the product information of medroxyprogesterone acetate (MPA)-containing products be amended by updating the safety warnings to include the potential risk of meningioma. 

SAHPRA clarifies the benefits and risks of medroxyprogesterone acetate - 17 January 2025

SAHPRA has approved the country's first WHO Emergency Use Listed test-kit for Mpox. Dr Dimakatso Mathibe and Ms Khanysile Nkuku share more.

Mpox test-kit in South Africa

SAHPRA was notified of the Lancet Global Health 2025; 13: e1250, an investigational study and its findings on substandard anti-cancer medications in Sub-Saharan African countries, including Ethiopia, Kenya, Malawi, and Cameroon. This study did not include South Africa. The seven (7) medicines/dosage forms mentioned in the study are cisplatin, oxaliplatin, methotrexate, doxorubicin, cyclophosphamide, ifosfamide, and leucovorin. The specific brands mentioned/shown in the article are neither registered nor marketed in South Africa.

SAHPRA‘s position on anti cancer medications in South Africa

Oteng Sebotwane and Raymond Birkenstock hosted a special interview where they discussed how medicine safety began with individual responsibility. They explained what side effects were and provided information on how to report side effects to SAHPRA with Audrey Chigome from SAHPRA

Rainbow FM - Pharmacovigilance interview with Audrey Chigome

Rainbow FM - Pharmacovigilance interview with Audrey Chigome Part 3

Oteng Sebotwane and Raymond Birkenstock hosted a special interview where they discussed how medicine safety began with individual responsibility. They explained what side effects were and provided information on how to report side effects to SAHPRA with Audrey Chigome from SAHPRA.

Rainbow FM - Pharmacovigilance interview with Audrey Chigome Part 2

In conversation with Zintle Mzileni, South African Health Products Regulatory Authority (SAHPRA), she joins Vukani FM to talk about medicine safety, why it starts with YOU, and how you can report side effects to SAHPRA.

Vukani FM interview with Zintle Mzileni - Medicine Safety Part 1

Vukani FM interview with Zintle Mzileni - Medicine Safety Part 2

A discussion with Ms Daphney Fafudi from SAHPRA about Substandard and falsified medical products with Daphney Fafudi on Alex FM

Substandard and falsified medical products with Daphney Fafudi- Alex FM

In conversation with Sasani Chauke, Medicine Registration Officer from the South African Health Products Regulatory Authority (SAHPRA), she joins Giyani FM to talk about medicine safety, why it starts with YOU, and how you can report side effects to SAHPRA.


GiyaniFM interview with Sasani Chauke on medicine safety

In conversation with Florah Matlala, Manager: Pharmacovigilance Unit from the South African Health Products Regulatory Authority (SAHPRA), she joins Mahikeng FM to talk about medicine safety, why it starts with YOU, and how you can report side effects to SAHPRA.

MahikengFM interview with Florah Matlala on Medicine Safety

Daphney Fafudi, Manager: Regulatory Compliance, was interviewed by Kaya FM on GLP-1 medicines in relation to weight loss. 

Kaya FM interview - GLP-1 medicines in relation to weight loss

SAHPRA is pleased to announce the registration of Lenacapavir. Lenacapavir is an antiviral medicine that is recommended, in combination with safer sex practices, for pre-exposure prophylaxis (PrEP) to prevent HIV-1 infection in adults and adolescents weighing at least 35 kg.

SAHPRA Registers Lenacapavir

The South African Health Products Regulatory Authority (SAHPRA) cautions members of the public against purchasing or using GLP-1 (glucagon-like peptide-1) products that are being promoted and sold on various social media platforms. These products are being promoted to assist with weight loss.

SAHPRA

Popular tracks